OPKO Health’s (OPK) Outperform Rating Reiterated at Barrington Research

Barrington Research restated their outperform rating on shares of OPKO Health (NASDAQ:OPK) in a report issued on Friday,Benzinga reports. The brokerage currently has a $2.25 price target on the biotechnology company’s stock. Barrington Research also issued estimates for OPKO Health’s FY2028 earnings at $0.00 EPS.

Several other equities analysts also recently weighed in on OPK. HC Wainwright restated a “buy” rating and set a $3.00 price target on shares of OPKO Health in a report on Thursday, September 26th. Piper Sandler reaffirmed an “overweight” rating and issued a $3.00 target price on shares of OPKO Health in a report on Tuesday, September 17th. Finally, StockNews.com upgraded shares of OPKO Health to a “sell” rating in a report on Saturday, July 27th.

OPKO Health Stock Up 3.3 %

Shares of OPKO Health stock opened at $1.57 on Friday. OPKO Health has a 1 year low of $0.85 and a 1 year high of $1.75. The firm has a market cap of $1.09 billion, a price-to-earnings ratio of -8.26 and a beta of 1.65. The company has a 50-day moving average of $1.51 and a 200 day moving average of $1.42. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.63 and a quick ratio of 1.36.

Insiders Place Their Bets

In related news, CEO Phillip Md Et Al Frost bought 280,183 shares of the company’s stock in a transaction that occurred on Friday, November 8th. The shares were bought at an average price of $1.50 per share, for a total transaction of $420,274.50. Following the completion of the acquisition, the chief executive officer now owns 211,512,405 shares of the company’s stock, valued at $317,268,607.50. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, CEO Phillip Md Et Al Frost bought 280,183 shares of the stock in a transaction on Friday, November 8th. The shares were bought at an average price of $1.50 per share, with a total value of $420,274.50. Following the completion of the acquisition, the chief executive officer now owns 211,512,405 shares in the company, valued at $317,268,607.50. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Opko Health, Inc. sold 50,000 shares of the firm’s stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $34.49, for a total value of $1,724,500.00. Following the completion of the transaction, the insider now directly owns 2,646,972 shares in the company, valued at $91,294,064.28. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 47.26% of the stock is owned by insiders.

Institutional Trading of OPKO Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Rubric Capital Management LP increased its position in OPKO Health by 800.0% in the second quarter. Rubric Capital Management LP now owns 44,422,304 shares of the biotechnology company’s stock worth $55,528,000 after buying an additional 39,486,490 shares in the last quarter. Y.D. More Investments Ltd bought a new stake in OPKO Health during the 2nd quarter worth approximately $1,840,000. Assenagon Asset Management S.A. lifted its holdings in OPKO Health by 142.5% during the third quarter. Assenagon Asset Management S.A. now owns 1,490,992 shares of the biotechnology company’s stock valued at $2,227,000 after purchasing an additional 876,272 shares in the last quarter. Squarepoint Ops LLC bought a new position in shares of OPKO Health in the second quarter worth approximately $592,000. Finally, Exchange Traded Concepts LLC raised its position in shares of OPKO Health by 135.7% during the 3rd quarter. Exchange Traded Concepts LLC now owns 387,108 shares of the biotechnology company’s stock valued at $577,000 after purchasing an additional 222,869 shares during the period. 64.63% of the stock is owned by hedge funds and other institutional investors.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.